HUE056798T2 - Imatinib stroke kezelésében való alkalmazásra - Google Patents

Imatinib stroke kezelésében való alkalmazásra

Info

Publication number
HUE056798T2
HUE056798T2 HUE17760399A HUE17760399A HUE056798T2 HU E056798 T2 HUE056798 T2 HU E056798T2 HU E17760399 A HUE17760399 A HU E17760399A HU E17760399 A HUE17760399 A HU E17760399A HU E056798 T2 HUE056798 T2 HU E056798T2
Authority
HU
Hungary
Prior art keywords
imatinib
stroke
treatment
Prior art date
Application number
HUE17760399A
Other languages
English (en)
Hungarian (hu)
Inventor
Ulf Eriksson
Nils Gunnar Wahlgren
Original Assignee
Hamra Invest Ab
Brain Consultant Nils Gunnar Wahlgren Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamra Invest Ab, Brain Consultant Nils Gunnar Wahlgren Ab filed Critical Hamra Invest Ab
Publication of HUE056798T2 publication Critical patent/HUE056798T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE17760399A 2016-02-29 2017-02-27 Imatinib stroke kezelésében való alkalmazásra HUE056798T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke

Publications (1)

Publication Number Publication Date
HUE056798T2 true HUE056798T2 (hu) 2022-03-28

Family

ID=59744327

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17760399A HUE056798T2 (hu) 2016-02-29 2017-02-27 Imatinib stroke kezelésében való alkalmazásra

Country Status (17)

Country Link
US (2) US10953010B2 (enExample)
EP (1) EP3423060B1 (enExample)
JP (1) JP6914957B2 (enExample)
CN (2) CN119523986A (enExample)
AU (1) AU2017227515B2 (enExample)
DK (1) DK3423060T3 (enExample)
ES (1) ES2895432T3 (enExample)
HR (1) HRP20211621T1 (enExample)
HU (1) HUE056798T2 (enExample)
LT (1) LT3423060T (enExample)
PL (1) PL3423060T3 (enExample)
PT (1) PT3423060T (enExample)
RS (1) RS62465B1 (enExample)
RU (1) RU2739382C1 (enExample)
SE (1) SE539450C2 (enExample)
SI (1) SI3423060T1 (enExample)
WO (1) WO2017151043A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN114306342B (zh) * 2020-09-30 2024-06-28 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
CN118524852A (zh) * 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
EP2021028A2 (en) 2006-04-17 2009-02-11 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP2076507A2 (en) * 2006-10-26 2009-07-08 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
TR201911199T4 (tr) * 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.

Also Published As

Publication number Publication date
PT3423060T (pt) 2021-10-20
RS62465B1 (sr) 2021-11-30
AU2017227515B2 (en) 2022-03-24
ES2895432T3 (es) 2022-02-21
JP2019507165A (ja) 2019-03-14
SE539450C2 (en) 2017-09-26
LT3423060T (lt) 2021-11-10
CN108697711A (zh) 2018-10-23
RU2739382C1 (ru) 2020-12-23
JP6914957B2 (ja) 2021-08-04
CN119523986A (zh) 2025-02-28
EP3423060B1 (en) 2021-07-21
US10953010B2 (en) 2021-03-23
DK3423060T3 (da) 2021-10-25
SE1650260A1 (en) 2017-08-30
WO2017151043A1 (en) 2017-09-08
AU2017227515A1 (en) 2018-08-30
EP3423060A1 (en) 2019-01-09
SI3423060T1 (sl) 2021-11-30
US20210236488A1 (en) 2021-08-05
EP3423060A4 (en) 2020-01-01
US20190030030A1 (en) 2019-01-31
PL3423060T3 (pl) 2022-01-10
HRP20211621T1 (hr) 2022-02-04

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
PL3265053T3 (pl) Sposoby leczenia skóry
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
EP3564335A4 (en) SURFACE TREATMENT AGENT
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3474802T3 (da) Medicinsk forbinding
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
EP3409744A4 (en) SURFACE TREATMENT AGENT
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
EP3431566A4 (en) SURFACE TREATMENT AGENT
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3408265T3 (da) Terapeutiske forbindelser
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE057257T2 (hu) Folyékony készítmény gyomor- és nyelõcsõ reflux kezelésében történõ alkalmazásra
EP3630331C0 (en) FLUID TREATMENT
DK3302478T3 (da) Pac-1 kombinations behandling
IL251345B (en) Compositions for use in the treatment of peri-implantitis
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
EP3356472C0 (en) PARTICLE SURFACE TREATMENT
DK3432901T3 (da) Sekventiel antikræftbehandling
LT3405197T (lt) Delgocitinibo panaudojimas lėtinės rankų egzemos gydymui